BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 9429864)

  • 1. Polycystic ovary syndrome.
    Goudas VT; Dumesic DA
    Endocrinol Metab Clin North Am; 1997 Dec; 26(4):893-912. PubMed ID: 9429864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome.
    Gordon CM
    Pediatr Clin North Am; 1999 Jun; 46(3):519-43. PubMed ID: 10384805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What every physician should know about polycystic ovary syndrome.
    Rosenfield RL
    Dermatol Ther; 2008; 21(5):354-61. PubMed ID: 18844713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
    Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
    Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gonadotropic axis in hyperandrogenic adolescents.
    Taylor AE
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1281-4. PubMed ID: 11117670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and the polycystic ovary syndrome.
    Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
    Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the PCOS phenotype with age.
    Hsu MI
    Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome.
    Kahn JA; Gordon CM
    Adolesc Med; 1999 Jun; 10(2):321-36. PubMed ID: 10370713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.
    Abbott DH; Rayome BH; Dumesic DA; Lewis KC; Edwards AK; Wallen K; Wilson ME; Appt SE; Levine JE
    Hum Reprod; 2017 Apr; 32(4):923-936. PubMed ID: 28333238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
    Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A
    J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia.
    Dunaif A; Graf M; Mandeli J; Laumas V; Dobrjansky A
    J Clin Endocrinol Metab; 1987 Sep; 65(3):499-507. PubMed ID: 3305551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approach to polycystic ovary syndrome and other forms of anovulatory infertility.
    Laven JS; Imani B; Eijkemans MJ; Fauser BC
    Obstet Gynecol Surv; 2002 Nov; 57(11):755-67. PubMed ID: 12447098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
    Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
    Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.